ICU nurses simultaneously pregnant at Mesa hospital
MPs call for e-cigarettes to be made available on prescription
How cutting carbs can increase the risk of early death
Mass overdose of marijuana sees 76 'bodies dropping' in park
World's oldest cheese found in Egyptian tomb
FDA greenlights Louisville company's drug for opioid withdrawal
18 May 2018, 03:59 | Melissa Porter
Robert F. Bukaty AP
It reduces the release of norepinephrine, a hormone believed to play a key role in triggering withdrawal symptoms.
The FDA still wants Lucemyra to conduct some safety studies to see the effects on children.
"As part of our commitment to support patients struggling with addiction, we're dedicated to encouraging innovative approaches to help mitigate the physiological challenges presented when patients discontinue opioids", said FDA Commissioner Scott Gottlieb, MD, in an agency release. Less common reactions could include fainting and abnormal heart rhythms. The wellbeing and viability of Lucemyra have not been built up in kids or young people under 17 years old. Patients' symptoms were evaluated according to the Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop), which included feeling sick, stomach cramps, muscle spasms/twitching, feeling of coldness, heart pounding, muscular tension, aches and pains, yawning, runny eyes and insomnia/problems sleeping.
"The fear of experiencing withdrawal symptoms often prevents those suffering from opioid addiction from seeking help".
On May 16, the Food and Drug Administration (FDA) approved of the first non-opioid treatment for adults suffering from opioid withdrawal symptoms. The treatment is to be provided only for 14 days. And those who seek assistance may relapse due to continued withdrawal symptoms.
The FDA is considering coming up with a strategy in the next few months to encourage medical professional societies to create evidence-based guidelines on how to prescribe medications for acute medical needs and assess prescribing behavior as well as adding new prescribing information to opioid labels.
The FDA requires a further 15 postmarketing studies to check for the safety of the drug.
For patients using opioids appropriately, withdrawal is usually managed by slow reduction in doses.
US WorldMeds - a former Vogt Award victor in Louisville - "has been developing the data needed for FDA approval for over 10 years", he said, adding, "Being a Louisville-based company is a main priority and one of the core mission visions of US WorldMeds". Patients can experience any combination of these symptoms after ceasing opioid use.
Lucemyra (lofexidine hydrochloride), therefore, represents a win for both the agency and US WorldMeds, which has just a handful of marketed products.
The FDA granted Lucemyra the go-ahead after previous priority review and fast track designations, and it comes after an independent scientific panel voted 11-1 in favor of its approval.
Because Lucemyra can make withdrawal process easier for patients, National Institute on Drug Abuse Director Nora Volkow, M.D., argues it could boost wider use of Vivitrol, which differentiates itself from methadone and buprenorphine, two other addiction treatments that belong to the opioid family.
Children were on bus that crashed with truck
Thursday on I-80 West in Mount Olive Township, with the bus ending up on its side in the grass median. The extent of the injuries is unknown, but at least two victims have life-threatening injuries.
Israel launches new air raid on Hamas in Gaza
For over half a century, since the 1967 war, Israel has occupied and dominated the territories of the West Bank and Gaza . Haley, however, blamed the violence on "those who reject the existence of the state of Israel ".